The Business Research Company’s global market reports provide comprehensive analysis on the various markets in 27 industries across 60 geographies.

The self-administered parenteral market is experiencing robust growth, expanding from $23.14 billion in 2023 to $24.57 billion in 2024, at a compound annual growth rate (CAGR) of 6.1%.

• Market Growth: $23.14 billion in 2023 to $24.57 billion in 2024
• CAGR: 6.1%

Historical Growth Drivers

Several factors have contributed to the market’s growth in recent years.

• Chronic Diseases: Increasing prevalence of chronic conditions
• Aging Population: Rising number of elderly individuals
• Government Initiatives: Policies to promote patient self-management
• Patient Education: Programs to educate and support patients
• Bone Disorders: Higher incidences of related health issues

Future Market Projections

The self-administered parenteral market is poised for steady growth, projected to reach $29.8 billion by 2028, at a CAGR of 4.9%.

• Market Projection: $29.8 billion by 2028
• CAGR: 4.9%

View More On The Self-Administered Parenteral Market Report 2024 – https://www.thebusinessresearchcompany.com/report/self-administered-parenteral-global-market-report

Forecasted Growth Drivers

Key factors expected to drive future market growth include:

• Home Healthcare: Increasing preference for home-based care
• Telemedicine: Growth of remote patient monitoring
• Patient Initiatives: Continued education and support
• Personalized Medicine: Expansion of tailored treatments

Major Trends in the Market

Several significant trends are expected to shape the market landscape.

• Digital Health Solutions: Integration of advanced technologies
• Customized Drug Delivery: Development of tailored delivery systems
• Targeted Therapies: Emergence of precise treatment options
• Biologics Advancements: Innovations in biological medications

Chronic Diseases Fuel Market Expansion

The prevalence of chronic diseases significantly contributes to market growth.

• Disease Management: Self-administered parenterals improve adherence
• Population Statistics: Expected increase in chronic disease cases among those aged 50 and above
  • 5% increase in chronic disease cases from 2020 to 2050

Key Market Players

Several major companies are prominent in the self-administered parenteral market.

• Leading Companies: Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., Sanofi S.A., and AstraZeneca PLC

Innovative Autoinjector Solutions

Companies are focusing on innovative products to enhance patient treatment.

• Example Product: UDENYCA autoinjector by Coherus BioSciences Inc.
  • Features: Intuitive design, fast dosing, at-home and in-office use

Halozyme Therapeutics’ Strategic Acquisition

Halozyme Therapeutics Inc. acquired Antares Pharma Inc. to strengthen its market position.

• Acquisition Value: $960 million
• Objective: Expand platform technologies and capabilities

Market Segmentation

The self-administered parenteral market is segmented into several categories.

• By Product: Pre-Filled Syringes, Autoinjectors, Pen Injectors, Other Products
• By Usage: Disposable, Reusable
• By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Home Healthcare Providers, Specialty Clinics, Other Channels
• By Application: Cardiovascular Diseases, Diabetes, Osteoporosis, Pain Management, Hormone Replacement, Other Applications

Regional Insights

North America was the largest region in the self-administered parenteral market in 2023.

• Leading Region: North America

Conclusion

The self-administered parenteral market is on a growth trajectory, driven by increasing chronic diseases, technological advancements, and strategic acquisitions. With ongoing innovations and rising patient preference for home healthcare, the market is set to continue its expansion in the coming years.

Request A Sample Of The Global Self-Administered Parenteral Market Report 2024:
https://www.thebusinessresearchcompany.com/sample_request?id=13927&type=smp